Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 3/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059713 | 0.92 | GPBAR1 (0.32) | GPBAR1P2RX7KCNJ11 | |
| SCHEMBL25085582 | 0.92 | GPBAR1 (0.32) | GPBAR1 | |
| SCHEMBL23059746 | 0.88 | GPBAR1 (0.36) | GPBAR1P2RX7MLYCD | |
| SCHEMBL25085499 | 0.86 | GPBAR1 (0.31) | GPBAR1 | |
| SCHEMBL25085569 | 0.86 | AR (0.32) | GPBAR1 | |
| SCHEMBL23059753 | 0.85 | GPBAR1 (0.31) | GPBAR1 | |
| SCHEMBL25085598 | 0.85 | AR (0.32) | GPBAR1 | |
| SCHEMBL23059628 | 0.84 | GPBAR1 (0.34) | GPBAR1LCKP2RX7BRAFKDR | |
| SCHEMBL23059629 | 0.84 | GPBAR1 (0.34) | GPBAR1P2RX7AURKAAURKB | |
| SCHEMBL25085576 | 0.82 | GPBAR1 (0.32) | GPBAR1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | DDT, INMT, CYP2B6 | GPBAR1 952/4885LCK 2077/4885P2RX7 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.